Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 4,000,000 shares, a growth of 151.6% from the November 30th total of 1,590,000 shares. Based on an average daily trading volume, of 93,440,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.1% of the shares of the company are short sold.

Tonix Pharmaceuticals Trading Down 8.8 %

Shares of NASDAQ TNXP traded down $0.03 during midday trading on Friday, hitting $0.34. The stock had a trading volume of 73,979,242 shares, compared to its average volume of 30,416,361. The company’s 50-day simple moving average is $0.22 and its 200 day simple moving average is $0.39. The firm has a market cap of $63.10 million, a P/E ratio of -0.01 and a beta of 2.23. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $14.08. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Research analysts anticipate that Tonix Pharmaceuticals will post -17.63 EPS for the current year.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Monday, December 23rd. They issued a “hold” rating for the company.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.